The DOI matches its Crossref record; its reference list is not available; 59 of the 233 sources its claims cite were checked for support.
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Open accessAbstract
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) are under development for T2D and obesity management. AREAS COVERED: Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management. EXPERT OPINION: We are in a new era in T2D management where entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D. Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.
Overview
CoChat Summary
TL;DR
This narrative review summarizes oral GLP-1 receptor agonists and injectable combinations of entero-pancreatic hormones for adults with type 2 diabetes, highlighting tirzepatide as the first approved dual GLP-1/GIP agonist and multiple phase 2/3 pipeline agents. It concludes that these therapies can achieve euglycemia and ≥15% weight loss for many patients, but long-term safety, cardiovascular/renal outcomes, and cost-effectiveness data are still needed.
Key findings
- Oral semaglutide 50 mg once daily produced a mean HbA1c reduction of 2.1% and 9.8% weight loss versus 1.3% and 5.4% with oral semaglutide 14 mg; 55% versus 32% achieved HbA1c ≤6.5%, and 42% versus 16% achieved ≥10% weight loss.
- Orforglipron, an oral non-peptide GLP-1 RA, reduced HbA1c by −1.19% to −2.10% and body weight by up to 9.6% at 45 mg in a 26-week phase 2 trial, with 12–19% discontinuing due to adverse events.
- Tirzepatide reduced HbA1c by up to 2.6%, with 70–94% achieving HbA1c ≤6.5% at 15 mg; mean weight loss ranged from −11.7 kg to −12.9 kg at 52 weeks, and up to 43% achieved ≥15% weight loss. In SURPASS-2, 38% on tirzepatide 15 mg achieved HbA1c ≤6.5% plus ≥15% weight loss without hypoglycemia versus 7% on semaglutide 1 mg.
- Among combination agents, cagrisema (cagrilintide 2.4 mg/semaglutide 2.4 mg) reduced HbA1c by −2.2% and weight by 15.6% versus semaglutide 2.4 mg (−1.8%, 5.1%) and cagrilintide 2.4 mg (−0.9%, 8.1%); retatrutide reduced HbA1c up to −2.2% and weight up to 16.9% versus dulaglutide 1.5 mg (−1.4%, 2%) and placebo (−0.3%, 3%).
Methods
- Narrative review of published phase 2 and phase 3 clinical trials of oral GLP-1 RAs (oral semaglutide 25/50 mg, orforglipron) and dual/triple entero-pancreatic hormone agonists (tirzepatide, cagrisema, survodutide, mazdutide, retatrutide) in adults with type 2 diabetes and/or obesity.
- Data are summarized in tables of trial design, baseline characteristics, efficacy outcomes (HbA1c, weight loss, blood pressure), and safety outcomes (adverse events, serious adverse events, discontinuations).
- Main analysis is a qualitative synthesis of trial results, ongoing phase 3 programs, and expert opinion on positioning, knowledge gaps, and future directions.
Limitations
- The paper states that long-term safety and efficacy, cardiovascular and renal outcomes, cost-effectiveness, and effects on lean muscle mass require further investigation; phase 2 trials had short follow-up (16–36 weeks) without evidence of weight-loss plateau.
- The paper notes that most phase 2/3 trials in type 2 diabetes were conducted in populations with obesity (mean baseline BMI 32–36 kg/m², except the mazdutide study in a Chinese population), so efficacy in lean people with type 2 diabetes is not adequately studied.
- Evident from the text: this is a narrative review without a systematic search or meta-analysis, and many included agents are still in phase 3, so comparative efficacy and safety versus approved therapies remain incomplete.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
36 Valid · 6 Not valid · 118 Not checked · 14 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Oral semaglutide 50 mg resulted in mean HbA1c reduction of 2.1% and mean WL of 9.8% compared to 1.3% HbA1c reduction and 5.4% WL with oral semaglutide 14 mg (Table 2, Figure 3) [23].”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Oral GLP-1 receptor agonists > Oral semaglutide
What the sources say
- Disputedcites [23] Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet Lond Engl. 2023; 402: 693– 704. doi: 10.1016/S0140-6736(23)01127-3 37385279 sourceExperimental — accuracy not yet measured
The Results report week-52 mean HbA1c reductions of 2.0 percentage points with 50 mg and 1.5 with 14 mg for the primary treatment-policy estimand. They report 2.2 and 1.5 points, respectively, for the trial-product estimand. Neither analysis gives the claimed 2.1 and 1.3, although both support a greater reduction with 50 mg. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Mean WL ranged from −11.7 kg to −12.9 kg with tirzepatide 15 mg at 52 weeks and up to 43% of people with T2D achieved ≥ 15% WL, even if tirzepatide was not combined with a lifestyle intervention at SURPASS programme.”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Combination of entero-pancreatic hormones > GLP-1 and GIP agonists
What the sources say
- Not checked yetcites [40] Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503– 515. doi: 10.1056/NEJMoa2107519. 34170647 • Phase 3 trial comparing the dual agonist tirzepatide with the GLP-1 RA semaglutide 1mg for type 2 diabetes management source
- Not checked yetcites [41] Rosenstock J, Wysham C, Frífrías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398(10295): 143– 155. doi: 10.1016/S0140-6736(21)01324-6 34186022 source
- Disputedcites [42] Rosenstock J, Frífrías JP, Rodbard HW, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023; 330(17): 1631. doi: 10.1001/jama.2023.20294 37786396 PMC10548360 sourceExperimental — accuracy not yet measured
The Additional Secondary and Exploratory End Points section reports that 13%–37% of tirzepatide-treated participants achieved at least 15% weight loss, not up to 43%. Key Secondary Outcomes reports a mean loss of 11.0 kg with 15 mg at week 52, not 11.7–12.9 kg. The cited trial therefore supports substantial weight loss, but its reported figures contradict those attributed to it; the passages have no page numbers. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [43] Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022; 327(6): 534– 545. doi: 10.1001/jama.2022.0078 35133415 PMC8826179 sourceExperimental — accuracy not yet measured
The Additional Secondary and Exploratory End Points section reports that 7%–24% of tirzepatide recipients achieved at least 15% weight loss at week 40, not up to 43%. The Abstract reports mean weight loss of 8.8 kg with 15 mg at week 40, rather than 11.7–12.9 kg at 52 weeks. The paper supports weight loss with tirzepatide in people with type 2 diabetes, but not the cited figures; these results are from SURPASS-5, not the programme as a whole. (LLM, conf=0.88)
- Not checked yetcites [44] Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet Lond Engl. 2021; 398: 583– 598. doi: 10.1016/S0140-6736(21)01443-4 34370970 source
- Not checked yetcites [45] Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Lond Engl. 2021; 398: 1811– 1824. doi: 10.1016/S0140-6736(21)02188-7 34672967 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Studies in animals have also shown an anorexigenic effect of the GIP and in preclinical studies, the simultaneous activation of GLP-1 and GIP receptors leads to enhanced glucose-lowering effects and more WL compared to activating either receptor alone [21,38,39].”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Combination of entero-pancreatic hormones > GLP-1 and GIP agonists
What the sources say
- Supportedcites [21] Sinha R, Papamargaritis D, Sargeant JA, et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023; 32(1): 25– 45. doi: 10.7570/jomes22067 36750526 PMC10088547 source
The GLP-1 AND GIP COMBINATION section states that preclinical studies found GIP receptor agonism reduced food intake, supporting the claimed anorexigenic effect in animals. No page number is provided in our copy. (LLM, conf=0.93)
- Supportedcites [38] Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021; 33(4): 833.e5– 844.e5. doi: 10.1016/j.cmet.2021.01.015 33571454 PMC8035082 source
The Discussion reports that fatty acyl-GIP administration decreased food intake in mice and that this effect depended on CNS GIP receptors. This supports the attributed animal finding, specifically for a GIP analog rather than unmodified GIP. (LLM, conf=0.92)
- Disputedcites [39] Gault VA, Kerr BD, Harriott P, et al. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci Lond Engl. 2011; 121(3): 107– 117. doi: 10.1042/CS20110006 21332446 sourceExperimental — accuracy not yet measured
The Discussion reports that the GIP analogue N-AcGIP(Lys 37 Myr) did not affect food intake or body weight in obese diabetic mice. It says this corroborates findings that GIP does not affect feeding activity, contrary to the attributed anorexigenic effect. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Introduction
What the sources say
- Supportedcites [12] Papamargaritis D, le Roux CW, Holst JJ, et al. New therapies for obesity. Cardiovasc Res. 2024; 119(18): 2825– 2842. doi: 10.1093/cvr/cvac176 36448672 PMC10874276 source
The section 'Obesity treatments > The example of bariatric surgery' identifies sleeve gastrectomy and Roux-en-Y gastric bypass as the two most commonly performed bariatric procedures (~85% worldwide) and reports their sustained long-term weight loss (RYGB 25-27%, SG ~20%). The same section states that bariatric surgery produces 'multiple clinically important benefits' — 53% reduction in fatal and 33% in total cardiovascular events, 29% reduction in mortality, 35% lower new-onset heart failure and 29% lower new-onset atrial fibrillation — and that these benefits are consistent across matched-cohort studies 'especially in people with obesity and T2D'. Figure 2 legend likewise plots SG and RYGB outcomes in adults with type 2 diabetes (refs 112-113). The cardiometabolic-benefit figures derive from bariatric-surgery cohorts (SOS, largely band/gastroplasty) rather than SG- and RYGB-specific trials, a level-of-specificity nuance, but the attributed point is stated in our copy. (LLM, conf=0.87)
- Partly supportedcites [13] Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013; 273(3): 219– 234. doi: 10.1111/joim.12012 23163728 sourceExperimental — accuracy not yet measured
Our copy of the SOS review supports the gastric-bypass half of the claim: the Weight changes section reports 10- and 15-year weight losses of 25 ± 11% and 27 ± 12% after GBP, and the Conclusions state that bariatric surgery has 'dramatic positive effects on most but not on all cardiovascular disease risk factors over a 10-year period', with favourable effects on established diabetes, diabetes prevention, and reduced cardiovascular events, cancer incidence and overall mortality; the diabetes remission/prevention sections give the same picture for patients with obesity and T2D. However, the sleeve-gastrectomy half is not supported: the SOS surgical cohort consisted only of gastric bypass (13%), banding (19%) and vertical banded gastroplasty (68%) (Abstract; The SOS intervention study, Treatments), and a search for 'sleeve gastrectomy' returns no exact passage in our copy. The claim that these two procedures are 'the two most commonly performed bariatric procedures today' is likewise not stated in this review. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Introduction
What the sources say
- Supportedcites [12] Papamargaritis D, le Roux CW, Holst JJ, et al. New therapies for obesity. Cardiovasc Res. 2024; 119(18): 2825– 2842. doi: 10.1093/cvr/cvac176 36448672 PMC10874276 source
The Introduction explicitly says bariatric surgery is not feasible or scalable as a population-wide intervention. The bariatric-surgery section also notes that surgical capacity is insufficient to operate on everyone who qualifies. (LLM, conf=0.95)
- Partly supportedcites [13] Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013; 273(3): 219– 234. doi: 10.1111/joim.12012 23163728 sourceExperimental — accuracy not yet measured
The Conclusions state that most countries lack sufficient bariatric-surgery capacity and that limited resources make patient selection important. This supports a current population-level access constraint, but not the categorical claim that surgery cannot be scaled; the paper calls for making it more universally accessible. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
104 more claims · 29 with their cited sources checked
Create a free account to see all 174 claims and to verify the 171 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 52
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, the absence of clinically relevant hepatic or renal toxicity suggests that no dose adjustment is required in patients with mild to moderate hepatic or renal dysfunction, a practical advantage in routine clinical practice [34].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [34]
Experimental — accuracy not yet measuredIn the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“| Tirzepatide10, 15 mg(SURMOUNT-2) [53] | Placebo | 2539 |”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Oral GLP-1 receptor agonists > Oral semaglutide
Reported 2539 · recomputed 938
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Combination of entero-pancreatic hormones > GLP-1 and glucagon
“compared to −1.35% with dulaglutide and + 0.03% with placebo.”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Oral GLP-1 receptor agonists > Orforglipron
“−1.41 to −1.67 vs (i) −1.35 vs(ii) −0.03”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Oral GLP-1 receptor agonists > Oral semaglutide
“compared to 1.3% HbA1c reduction and 5.4% WL with oral semaglutide 14 mg”
§ Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? > Oral GLP-1 receptor agonists > Oral semaglutide
“−1.7% to −2.1% vs 1.3%”
Citations
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 99 · Cited by 32
Research works printed but not linked: 2
- Pfizer announces topline phase 2b results of oral GLP-1R agonist danuglipron in adults with obesity. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
- Pharmathene Inc. Historical Press Releases. Altimmune announces positive results from week 24 interim analysis of pemvidutide momentum phase 2 obesity trial and 12-week phase 1b type 2 diabetes safety trial. Available from: https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-results-week-24-interim-analysis
Metadata
- Authors
- Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2024-05-02
- Volume
- 25
- Issue
- 7
- Pages
- 801-818
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- PMC
- PMC11195668
- OpenAlex
- W4396977424
- Cited by
- 32
- References
- 99
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 7
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc-nd)
- Funders
- he National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, oral GLP-1 receptor agonists, semaglutide, orforglipron, tirzepatide, cagrilintide, survodutide, mazdutide, retatrutide, glucose-dependent insulinotropic polypeptide, glucagon, amylin, obesity treatment, weight loss, dual agonist, treatment algorithm
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Animals, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? https://app.cochat.ai/papers/10.1080/14656566.2024.2356254
- The paper
- Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024). Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2024.2356254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.